Ronald G. Thomas - Researcher Profile

Publications

2 shown

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Rachelle S. Doody , Ronald G. Thomas , Martin R. Farlow +10 more

Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov n...

2014 New England Journal of Medicine 1588 citations

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Rachelle S. Doody , Rema Raman , Martin R. Farlow +11 more

As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was...

2013 New England Journal of Medicine 1183 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 2,771
Institution: Alzheimer’s Disease Neuroimaging Initiative

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-1686-4965

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.